Neeraja Parameswaran

TL;DR: A new, experimentally based compilation of species-specific dose selection for studies on the in vivo effects of nicotine, addressing issues related to genetic background, age, acute vs chronic exposure, route of administration, and behavioral responses is provided.

TL;DR: The objective was to determine whether nicotine treatment reduced levodopa‐induced dyskinesias and to investigate the role of cholinergic interneurons in this development.

TL;DR: The results showed that levels of striatal tyrosine hydroxylase, dopamine transporter, vesicular monoamine transporter, dopamine and nicotinic receptors were greater in nicotine‐treated MPTP‐lesioned primates than in lesioned animals not receiving nicotine, indicating that nicotine acts at the striatal level to restore/maintain dopaminergic function.

TL;DR: Observations suggest that nAChR stimulation may represent a useful treatment strategy for Parkinson's disease for neuroprotection and symptomatic treatment, as only selective nA ChR subtypes are present in the striatum including the alpha4beta2*, alpha6beta2* and alpha7 nA cholinergic populations.

TL;DR: The present data suggest that the α 6* nAChR subtype represents a key factor in the control of dopamine release from striatum, which adapts to long-term nicotine treatment by down-regulation of α6* receptor sites and function.